Tettero, J. M., Ngai, L. L., Bachas, C., Breems, D. A., Fischer, T., Gjertsen, B. T., Gradowska, P., Griskevicius, L., Janssen, J. J., Juliusson, G., Maertens, J., Manz, M. G., Pabst, T., Passweg, J., Porkka, K., Valk, P. J., Löwenberg, B., Ossenkoppele, G. J. and Cloos, J. (2023) “Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival”, Haematologica. Pavia, Italy, 108(10), pp. 2794-2798. doi: 10.3324/haematol.2022.282639.